We don't follow trends, at Paso Alto we create them.
This new methodology has the potential to significantly advance medical science and the health sector.
Molecular Physical and Electronics in the service of medicine.
Paso Alto is a group of companies specialized in research in biophysical sciences and medical bioengineering that works in the development of new technologies applicable to healthcare for the treatment of diseases in its own network of centers.
In a first stage, we focus on the development of new therapy systems or methods that can be applied in processes to fight infectious diseases caused by viruses and, in a second stage, the equipment and processes were tuned for application related to oncology pathologies.
The company carries out its research and technological development work without belonging to any pharmaceutical structure or being part of centers, organizations or administrations of any kind, so that all the advances achieved in the different areas of action belong exclusively to the company, which in turn allows it to develop without being answerable to any external agent.
Research, development and innovation.
The research and development activity has been marked by the improvement of the technology developed and its application.
2024
Updating of Prototype II (MI-M) to extend the operational range and investigation of its application on mice model.
Extension of in vitro experiments and in vivo experiments with C57BL/6 mice and nude mice induced with Glioblastoma and Colon tumor cells.
First paper with experimental results is published in Scientific Reports / Nature.
The data linked to the last experimental phase - in vivo treatment - are kept under industrial secrecy.
Assessment of molecular modulation by multifrequency electromagnetic pulses to preferably eradicate tumorigenic cells | Scientific Reports
2023
Updating of “Prototype II” (MI-M) to extend the operational range and investigation of its application on cancer cells.”Prototype II” (MI-M) to extend the operational range and investigation of its application on cancer cells.
The experiments were carried out at the CBMSO (Centro de Biología Molecular Severo Ochoa, Madrid) with MI-M technology in different cancer cell lines. Given the results of this in vitro phase, the next step will be to experiment in a mouse model.
2022
Trial to study the efficacy of the two vaccine candidates obtained by (MI-M).
Clinical animal trials with the two candidate ASFV vaccines obtained by MI-M at the veterinary research laboratory in Lelystad (The Netherlands) begin.
Efficacy and safety of ASFV inactivation with the MI-M method is demonstrated, and a relevant result is obtained with the candidate vaccine, partially modulated NHP68.
2021
Modulation of ASFV with modulated molecular interaction technology (IM-M).
An experiment was carried out at the CBMSO (Centro de Biología Molecular Severo Ochoa, Madrid) with the “Prototype II” and two candidate vaccines against ASFV were obtained using modulated molecular interaction technology (MI-M).
1- With strain NPH68 partially modulated.
2- With fully modulated virulent ASFV strain.
2020
Development of the Molecular Interaction Modulator “Prototype II” (MI-M)
Development of "Prototype II" is completed. Device capable of interacting with RNA and DNA viruses contained in its characteristic media.
2018
Laboratory inactivation of Zika, Ross River and Yellow Fever viruses.
The experiments are carried out at the ISCIII (Instituto de Investigación y Salud Carlos III de Madrid) and at the IUETSPC (Instituto de enfermedades tropicales de Canarias) where in vitro inactivation of Zika, Ross River and Yellow Fiver virus samples is achieved using the "Prototype I".
2016
Development of the Molecular Interaction Modulator “Prototype I” (MI-M)
"Prototype I" of (MI-M), a device capable of interacting with RNA-type viruses contained in its characteristic media, is completed.
Managers
Luis G. Rodríguez Martínez
Founder & Manager
Degree in Physics Sciences and Electronics. Chief Executive Officer and Director of Research and Development of Paso Alto Biophysics (Spain) and Manager of the Paso Alto Group (USA).
Fidel Valdés
Founder & Manager
Telecommunications and Electronics Engineer. CEO and founder of the Paso Alto Advanced Treatment Center and Business Development of the Paso Alto Group (USA and Spain).
Rafael López
Founder & Manager
Economics studies, risk analyst and specialist in intellectual and industrial property in the biotechnology sector with experience in the banking sector. Current President and CFO of Paso Alto Biophysics and Biomedical Engineering (Spain) and Paso Alto Group (USA).
Linkage with:
